Impact of metastatic status on the prognosis of EGFR mutation‑positive non‑small cell lung cancer patients treated with first‑generation EGFR‑tyrosine kinase inhibitors

Abstract excerpt

The aim of the present study was to analyze the impact of metastatic status on the prognosis of epithelial growth factor receptor (EGFR) mutation‑positive patients with non‑small cell lung cancer (NSCLC) treated with first‑generation EGFR‑tyrosine kinase inhibitors (TKIs). A total of 178 EGFR mutation‑positive patients with stage IIIB‑IV and relapsed NSCLC who were treated with gefitinib or erlotinib as the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Colorectal Cancer Treatments and Studies
• Share to HER2/EGFR in Cancer Research
• Share to Lung Cancer Treatments and Mutations